Covalon Announces Voting Results from Fiscal 2023 Annual Meeting of Shareholders
Covalon Technologies Ltd. announces successful results of its Fiscal 2023 Annual Meeting of Shareholders, with all items of business approved. The voting results for the election of the Board of Directors and the appointment of auditors are detailed, showing high approval rates.
Positive
Successful approval of all items of business at Covalon's Fiscal 2023 Annual Meeting of Shareholders.
High voting percentages for the election of the Board of Directors and the appointment of auditors.
Detailed breakdown of the voting results for each nominee and the auditor.
Availability of further details on the voted matters in the Company's management information circular.
Recording of the AGM and management's presentation accessible on Covalon's website.
03/07/2024 - 07:00 AM
MISSISSAUGA, Ontario --(BUSINESS WIRE)--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2023 Annual Meeting of Shareholders (“AGM”) held March 6, 2024.
Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes. The matters included the election of the Board of Directors and the appointment of auditors. The total number of shares represented, either in person or by proxy, totaled 10,665,029 or 43.232% . The voting results are detailed below.
1) The Election of the Board of Directors
Name of Nominee
Votes FOR
%
Votes WITHHELD
%
Brent Ashton
10,481,118
99.811
19,800
0.189
Amir Boloor
10,405,326
99.090
95,592
0.910
Joseph Cordiano
10,363,626
98.693
137,292
1.307
Martin Goldfarb
10,350,326
98.566
150,592
1.434
Samantha Nutt
10,435,784
99.380
65,134
0.620
Abe Schwartz
10,182,126
96.964
318,792
3.036
Ron Smith
10,373,626
98.788
127,292
1.212
2) The Appointment of the Auditor
Votes FOR
%
Votes WITHHELD
%
PricewaterhouseCoopers,
LLP
10,661,208
99.983
1,800
0.017
Final voting results of all matters voted on at the meeting will be filed on SEDAR+ at http://www.sedarplus.ca/ and further details of the voted matters can be found in the Company’s management information circular January 30, 2024.
A recording of the AGM and a copy of management’s presentation are available on Covalon’s website at https://ir.covalon.com/events-and-presentations/events/event-details/2024/Annual-Meeting-of-Shareholders-2024-IEG2Kp8KHg .
Those interested in learning more about Covalon’s solutions may visit www.covalon.com or follow Covalon on LinkedIn , Facebook , or Instagram .
About Covalon
Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions that aim to help reduce pain, prevent infection, and promote healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection control, and medical device coatings, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com .
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca , any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307664149/en/
To learn more about Covalon:
Investor Relations, Covalon Technologies Ltd.
investors@covalon.com
https://covalon.com/
Source: Covalon Technologies Ltd.
What were the results of Covalon Technologies Ltd.'s Fiscal 2023 Annual Meeting of Shareholders?
Covalon announced successful voting results with all items of business approved.
How many shares were represented at the AGM?
A total of 10,665,029 shares, equivalent to 43.232%, were represented at the AGM.
Who were the nominees for the Election of the Board of Directors?
Nominees included Brent Ashton, Amir Boloor, Joseph Cordiano, Martin Goldfarb, Samantha Nutt, Abe Schwartz, and Ron Smith.
What was the voting percentage for the Appointment of the Auditor?
PricewaterhouseCoopers, LLP received a high approval rate of 99.983% for the Appointment of the Auditor.
Where can further details on the voted matters be found?
Additional details on the voted matters can be accessed in the Company's management information circular.
